Protalix BioTherapeutics, Inc. (PLX) 股票分析

公司概述

Protalix BioTherapeutics, Inc. operates as a biopharmaceutical entity dedicated to the development, production, and commercialization of recombinant therapeutic proteins utilizing the ProCellEx plant cell-based protein expression system. The company functions within the healthcare sector, specifically inside the biotechnology industry, positioning itself to leverage plant-based manufacturing for scalable protein production. Its current market capitalization stands at $172.42M, while annual revenue over the trailing twelve months amounts to $52.74M, supported by an employee base of 226 individuals. These financial figures indicate that the company occupies a niche position in the market, characterized by a relatively small market cap that reflects early-stage or specialized therapeutic focus rather than broad-based mass market dominance. The revenue figure of $52.74M suggests a specific product-driven revenue stream, primarily centered on its commercialization of Elelyso for Gaucher disease treatment, which defines its operational scope within the competitive biopharmaceutical landscape.

财务健康

The company reported a revenue of $52.74M over the trailing twelve months, yet recorded a net income of $-6,604,000 and an EBITDA of $-4,035,000. The substantial disparity between the positive revenue of $52.74M and the negative net income reveals a cost structure where operating expenses significantly exceed gross profits, a common characteristic in the development and commercialization phases of biotechnology firms. Free cash flow stands at $-12,196,875, indicating that the company is currently burning cash, which limits immediate financial flexibility and necessitates reliance on external financing or existing reserves to sustain operations. Gross margin is 13.0%, operating margin is -51.1%, and profit margin is -12.5%; the low gross margin suggests high cost of goods relative to sales, while the deeply negative operating and profit margins highlight intense pressure from research, development, and administrative costs. Total cash on hand is $30.27M, which partially offsets total debt of $8.32M, resulting in a debt-to-equity ratio of 17.25 that signals a leveraged balance sheet despite the cash buffer. The current ratio of 2.51 indicates that the company holds sufficient current assets to cover its short-term liabilities, providing a measure of short-term liquidity stability. Return on Equity is -14.4% and return on assets is -4.4%, metrics that reveal management is currently generating negative returns on the capital invested, reflecting the high-risk nature of the company's investment cycle before achieving significant profitability.

估值评估

The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is 3.45, implying that the market is pricing the stock based on anticipated future profitability rather than current performance. The price-to-book ratio stands at 3.57, indicating that the market values the company at a premium of roughly 3.57 times its net asset value, a multiple often seen in biotech firms with intangible assets like intellectual property. The price-to-sales ratio is 3.27, and the EV/EBITDA is -37.29; these alternative metrics suggest that valuation is driven by revenue generation potential and asset backing rather than earnings, given the negative earnings multiple. The 52-week high is $3.19 and the 52-week low is $1.32, placing the current trading price within a range that reflects significant volatility and uncertainty regarding the stock's immediate valuation path. The beta value is -0.23, which indicates an inverse correlation to the broader market, meaning the stock tends to move counter to general market trends, a unique characteristic that affects portfolio diversification strategies.

Growth & Income

Revenue growth year-over-year is -49.9%, while earnings growth year-over-year is N/A due to the lack of positive earnings data for comparison. The negative revenue growth rate suggests a contraction in sales, which currently outpaces any potential earnings improvement since earnings are negative. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%; this structure confirms that the company retains all earnings, though in this case, it is retaining losses to fund operations rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by revenue contraction and a complete absence of dividend income, relying entirely on the potential for future product approvals and market expansion to reverse the negative growth trajectory.